Orgenesis Current Ratio 2013-2021 | ORGS

Orgenesis current ratio from 2013 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Orgenesis Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.05B $0.02B 2.64
2021-03-31 $0.06B $0.02B 2.89
2020-12-31 $0.05B $0.02B 3.08
2020-09-30 $0.10B $0.01B 7.69
2020-06-30 $0.10B $0.02B 5.28
2020-03-31 $0.11B $0.03B 4.36
2019-12-31 $0.08B $0.04B 1.85
2019-09-30 $0.02B $0.02B 0.85
2019-06-30 $0.03B $0.02B 1.18
2019-03-31 $0.02B $0.02B 1.10
2018-12-31 $0.03B $0.02B 1.64
2018-11-30 $0.03B $0.02B 1.77
2018-08-31 $0.03B $0.02B 1.65
2018-05-31 $0.01B $0.01B 1.06
2018-02-28 $0.01B $0.02B 0.53
2017-11-30 $0.01B $0.02B 0.43
2017-08-31 $0.01B $0.02B 0.32
2017-05-31 $0.01B $0.02B 0.38
2017-03-31 $0.00B 0.00
2017-02-28 $0.00B 0.00
2016-12-31 $0.00B $0.02B 0.29
2016-11-30 $0.00B $0.02B 0.29
2016-09-30 $0.00B $0.02B 0.29
2016-08-31 $0.00B 0.00
2016-06-30 $0.00B 0.00
2016-05-31 $0.00B 0.00
2016-03-31 $0.00B 0.00
2015-12-31 $0.01B $0.02B 0.50
2014-12-31 $0.00B $0.01B 0.48
2013-12-31 $0.00B $0.00B 0.09
2012-12-31 $0.00B $0.00B 0.09
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.113B $0.008B
Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing Organization and Cellular Therapy Business. Contract Development and Manufacturing Organization segment activity includes MaSTherCell, which specializes in cell therapy development for advanced medicinal products. Cellular Therapy Business segment activity is based on its technology which demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes. Orgenesis, Inc. is headquartered in Germantown, MD.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76